BACKGROUND: Anti-programmed cell death (PD)-1 therapy is emerging as the backbone of new standard of care immunotherapy for metastatic melanoma. Immune-related cutaneous events are observed in these patients. OBJECTIVE: We sought to describe cutaneous adverse events observed in patients with metasta...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!